Document is current
Any future updates will be listed below
-
Authors
Khan, Parvez
Siddiqui, Jawed Akhtar
Lakshmanan, Imayavaramban
Ganti, Apar Kishor
Salgia, Ravi
Jain, Maneesh
Batra, Surinder Kumar
Nasser, Mohd Wasim https://orcid.org/0000-0003-2070-4972
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA218545)
National Cancer Institute (R01CA247471)
National Cancer Institute (R01CA247471)
National Cancer Institute (R01CA195586)
National Cancer Institute (R01CA195586)
National Cancer Institute (P01 CA217798)
National Cancer Institute (P01 CA217798)
National Cancer Institute (P30CA033572)
National Cancer Institute (U54CA209978)
National Cancer Institute (R01CA247471)
National Cancer Institute (R01CA218545)
National Cancer Institute (R01CA241752)
U.S. Department of Veterans Affairs (I01 BX004676)
- License Information
-
More Information
Article History
Received: 29 December 2020
Accepted: 23 February 2021
First Online: 19 March 2021
Declaration
:
: SKB is co-founder of Sanguine Diagnostics and Therapeutics, Inc. AKG is on the advisory board for Blueprint Medicines, Cardinal Health, AstraZeneca, and G1 Therapeutics. He has served as a consultant to AstraZeneca and Genentech, and received research support from Oncoceutics and Takeda Pharmaceuticals. Other authors declare no competing interests.
: Not applicable for this review.
: All authors agree with the content of the manuscript and consent to publication.
